Close Menu

NEW YORK — Magnolia Medical Technologies said on Thursday that it has received clearance from US regulators for its expanded Steripath Gen2 Initial Specimen Diversion Device line of blood contamination reduction products.

The Steripath Gen 2 ISDD is designed to divert and isolate a small volume of the initial blood collected for culture, which is the portion most likely to contain contaminants. According to Seattle-based Magnolia, the device has demonstrated as much as an 88 percent reduction in blood culture contamination compared to standard method controls in clinical testing.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.